Aurora Cannabis (ACB)
(Delayed Data from NSDQ)
$5.37 USD
-0.03 (-0.56%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $5.37 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.37 USD
-0.03 (-0.56%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $5.37 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 68.57% and 20.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 0.72% and 0.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Break-Even Earnings for Q2
by Zacks Equity Research
High Tide (HITI) delivered earnings and revenue surprises of 100% and 2.73%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Canopy Growth (CGC): Can Its 11.0% Jump Turn into More Strength?
by Zacks Equity Research
Canopy Growth (CGC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?
by Zacks Equity Research
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Aurora Cannabis Inc. (ACB) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) concluded the recent trading session at $6.46, signifying a -1.15% move from its prior day's close.
Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 16.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50% and 19.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho (QDEL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 4% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 11.11% and 2.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?